MV Biotherapeutics and Malcisbo agree to explore the Apyrase technology platform for AH Vaccines

MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant.

Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio proprietary Apyrase technology platform for their Campylobacter and Actinobacillus pleuropneumoniae (APP) vaccine candidates.